TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04167228

Intervention type: DRUG
Intervention: Ceftazidime-Avibactam
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with ceftazidime-avibactam.

Intervention type: DRUG
Intervention: Best Available Therapy
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
Study: NCT01001962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: ACTIVE TREATMENT FOR DIABETES

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: ACTIVE TREATMENT FOR DIABETES
Study: NCT01280747

Intervention type: OTHER
Intervention: prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate

Intervention type: OTHER
Intervention: no prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate

Intervention type: OTHER
Intervention: prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate

Intervention type: OTHER
Intervention: no prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate
Study: NCT04360798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Exercise Group
Description: Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Exercise Group
Description: Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
Study: NCT03973255

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Posturography, Whole body vibration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Posturography, Whole body vibration
Study: NCT04362098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting Program for Young Pregnant Women
Description: The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
Study: NCT01401114

Intervention type: DRUG
Intervention: E2/LNG oral (Wellnara, BAY86-5029)
Description: Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
Study: NCT04038749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural methods
Description: milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural methods
Description: milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.

Intervention type: OTHER
Group type: OTHER
Intervention: Natural methods
Description: milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
Study: NCT02051985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.
Study: NCT04240236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
Study: NCT00827775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
Study: NCT02198261

Intervention type: DRUG
Intervention: 5% minoxidil topical foam
Description: 5% minoxidil topical foam

Intervention type: DRUG
Intervention: 5% minoxidil topical foam
Description: 5% minoxidil topical foam
Study: NCT00945451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CK
Description: Cyberknife Irradiation
Study: NCT01963572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SG will be screened every time when they visit the clinics.
Study: NCT02604797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patient-controlled intravenous analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: patient-controlled intravenous analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen axetil
Description: patient-controlled intravenous analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen axetil
Description: patient-controlled intravenous analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: patient-controlled intravenous analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: patient-controlled intravenous analgesia
Study: NCT00694135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
Study: NCT03065036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prestudy topical glaucoma medications
Description: Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.

Intervention type: DRUG
Group type: OTHER
Intervention: prestudy topical glaucoma medications
Description: Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
Study: NCT02939976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vessel Disease
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-vessel Disease, Culprit Vessel Only
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
Study: NCT03123419

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Appointment reminders
Description: The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
Study: NCT03035318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Global® Anchor Peg Glenoid Instrumentation
Description: Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy Global® Anchor Peg Instrumentation with SmartBone™
Description: Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRI with SmartBone™
Description: Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTI with SmartBone™
Description: Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRI with SmartBase
Description: Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
Study: NCT01095913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
Study: NCT01530087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CASTLE barrier
Description: Prototype barrier to be used in place of current two piece device
Study: NCT04244422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEZOSURGERY VERSUS CONVENTIONAL SURGERY
Description: Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEZOSURGERY VERSUS CONVENTIONAL SURGERY
Description: Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
Study: NCT03142321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 MG Injection [Entyvio]
Description: Vedolizumab Injection
Study: NCT01980524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acipimox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT02169921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy Catheter
Description: Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm.
Study: NCT00690378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104/ceftazidime
Description: 125mg/500mg TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/Cilastatin
Description: 4 x daily
Study: NCT03964922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow sample
Description: 3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
Study: NCT01209741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telcagepant potassium
Description: \[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0974 5Mo5C
Description: Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0974 12Mo5C
Description: Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
Study: NCT03665753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subject will receive 10, 20, and 30mg of Ketorolac.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subject will receive 10, 20, and 30mg of Ketorolac.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subject will receive 10, 20, and 30mg of Ketorolac.
Study: NCT01607931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of cycling at 50% of maximum power output
Study: NCT00992121

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib 2 week
Description: Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib 3 week
Description: Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
Study: NCT04582513

Intervention type: OTHER
Intervention: AnCHor-Checklist implementation
Description: a standardized checklist using the SBAR concept according to the recommendations of the DGAI
Study: NCT04317001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Treatment will be with 100mg of modafinil for the two week primary phase of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02877264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 132 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 264 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 24 mg/mL oral suspension
Study: NCT01476124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine Placebo
Description: Morphine Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Description: Gabapentin enacarbil 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Description: Gabapentin enacarbil 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine extended release 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine extended release 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn Placebo
Description: Gabapentin enacarbil placebo
Study: NCT01860547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberries
Description: Frozen bilberries, 100 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn berry
Description: Dried sea buckthorn berries, 20 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolic extract
Description: Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil
Description: Sea buckthorn oil, 4 g (8 capsules)/d
Study: NCT03398421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Description: Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be given as 100 mg per capsule per day administered orally with water
Study: NCT03990298

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Awake endoscopy
Description: Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
Study: NCT02412111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Study: NCT04176783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: narcotic pain medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Free
Description: non narcotoc pain medication
Study: NCT00788164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-HPV
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-HPV
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given topically
Study: NCT05061069

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical vestibular evoked myogenic potentials (cVEMP)
Description: cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
Study: NCT03494855

Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.

Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.

Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.

Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.

Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.